AGP Executive Report
Last update: 9 hours agoHK IPO momentum: Guangdong TrueHealth Medical Technology (02697.HK) made a blockbuster HKEX debut, surging 216.96% to close at HK$400 after a first-day rally on percutaneous surgical robotics demand. Biotech pipeline: HUTCHMED said China’s NMPA granted conditional approval for ORPATHYS (savolitinib) for MET-amplified advanced gastric cancer patients after at least two prior treatments. Capital markets plumbing: Bloomberg flagged Hong Kong’s equity market divergence as fundraising stays strong while investors rotate away from AI-linked valuations; meanwhile, a separate report warned many mainland IPO hopefuls face CSRC approval delays and application expiry risk. Legal and governance: Legco lawmaker William Wong failed to report his drink-driving arrest to the legislature, triggering an internal probe. Professional services hiring: Sullivan & Cromwell added a Hong Kong capital markets partner from Paul Hastings, while White & Case rebuilt its disputes bench with hires from Broadfield. Regional business backdrop: Ogilvy’s APAC Believability Index found 93% of consumers disengage when brand trust slips, and Nvidia outlined a usage-linked revenue-sharing model to help smaller AI developers access compute. Metals hub push: LME is considering rule changes, including outside aluminium storage, to make Hong Kong a more viable warehouse location.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
